Genomic Vision (GV.PA) Fundamental Analysis & Valuation

EPA:GV • FR0011799907

Current stock price

0.0018 EUR
+0 (+5.88%)
Last:

This GV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GV.PA Profitability Analysis

1.1 Basic Checks

  • In the past year GV has reported negative net income.
  • GV had a negative operating cash flow in the past year.
GV.PA Yearly Net Income VS EBIT VS OCF VS FCFGV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M

1.2 Ratios

  • GV has a Return On Assets of -268.44%. This is amonst the worse of the industry: GV underperforms 89.74% of its industry peers.
Industry RankSector Rank
ROA -268.44%
ROE N/A
ROIC N/A
ROA(3y)-93.6%
ROA(5y)-88.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GV.PA Yearly ROA, ROE, ROICGV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

  • GV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GV.PA Yearly Profit, Operating, Gross MarginsGV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. GV.PA Health Analysis

2.1 Basic Checks

  • GV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GV has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for GV is higher compared to a year ago.
GV.PA Yearly Shares OutstandingGV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
GV.PA Yearly Total Debt VS Total AssetsGV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

  • GV has an Altman-Z score of -20.15. This is a bad value and indicates that GV is not financially healthy and even has some risk of bankruptcy.
  • GV has a worse Altman-Z score (-20.15) than 91.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.15
ROIC/WACCN/A
WACC5.63%
GV.PA Yearly LT Debt VS Equity VS FCFGV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 0.41 indicates that GV may have some problems paying its short term obligations.
  • The Current ratio of GV (0.41) is worse than 94.87% of its industry peers.
  • GV has a Quick Ratio of 0.41. This is a bad value and indicates that GV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GV has a worse Quick ratio (0.36) than 94.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.36
GV.PA Yearly Current Assets VS Current LiabilitesGV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. GV.PA Growth Analysis

3.1 Past

  • The earnings per share for GV have decreased strongly by -14.12% in the last year.
  • Looking at the last year, GV shows a small growth in Revenue. The Revenue has grown by 6.74% in the last year.
  • Measured over the past years, GV shows a very negative growth in Revenue. The Revenue has been decreasing by -13.68% on average per year.
EPS 1Y (TTM)-14.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.36%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-16.62%
Revenue growth 5Y-13.68%
Sales Q2Q%16.05%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GV.PA Yearly Revenue VS EstimatesGV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M
GV.PA Yearly EPS VS EstimatesGV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. GV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • GV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GV.PA Price Earnings VS Forward Price EarningsGV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GV.PA Per share dataGV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GV.PA Dividend Analysis

5.1 Amount

  • GV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GV.PA Fundamentals: All Metrics, Ratios and Statistics

Genomic Vision

EPA:GV (11/3/2023, 7:00:00 PM)

0.0018

+0 (+5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap693.19K
Revenue(TTM)1.11M
Net Income(TTM)-10.62M
Analysts35
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -268.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.6%
ROA(5y)-88.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.31%
Cap/Sales 32.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.36
Altman-Z -20.15
F-Score3
WACC5.63%
ROIC/WACCN/A
Cap/Depr(3y)27.39%
Cap/Depr(5y)20.59%
Cap/Sales(3y)11.06%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-16.62%
Revenue growth 5Y-13.68%
Sales Q2Q%16.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.92%
OCF growth 3YN/A
OCF growth 5YN/A

Genomic Vision / GV.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Genomic Vision (GV.PA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to GV.PA.


Can you provide the valuation status for Genomic Vision?

ChartMill assigns a valuation rating of 0 / 10 to Genomic Vision (GV.PA). This can be considered as Overvalued.


What is the profitability of GV stock?

Genomic Vision (GV.PA) has a profitability rating of 0 / 10.


What is the financial health of Genomic Vision (GV.PA) stock?

The financial health rating of Genomic Vision (GV.PA) is 0 / 10.